Format

Send to

Choose Destination
Acta Neurol Scand. 2013 Feb;127(2):e8-12. doi: 10.1111/ane.12012. Epub 2012 Sep 23.

Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies.

Author information

1
Department of Neurology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden. radu.constantinescu@vgregion.se

Abstract

BACKGROUND:

Low levels of serum urate are associated with a higher risk of Parkinson's disease (PD). Higher serum and cerebrospinal fluid (CSF) urate levels are associated with slower rates of clinical decline in PD and in multiple system atrophy (MSA).

AIMS:

To compare CSF and blood urate levels in healthy controls, patients with synucleinopathies and with tauopathies.

METHODS:

We investigated urate levels in serum and CSF from 18 healthy controls, 19 patients with synucleinopathies (six patients with PD and 13 with MSA), and 24 patients with tauopathies (18 with progressive supranuclear palsy and six with corticobasal degeneration). None of the patients were treated with dopaminergic medications.

RESULTS:

No significant differences were seen when comparing serum and CSF urate levels from controls across the parkinsonian diagnostic groups. However, in men, serum urate levels were significantly lower in the synucleinopathy group compared with the tauopathy group (P = 0.046), although with a broad overlap.

CONCLUSION:

Our study suggests that urate levels might provide new insights into the potential pathophysiological mechanisms underlying Parkinsonism and thereby contribute to the future management of these disorders.

PMID:
22998191
DOI:
10.1111/ane.12012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center